Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHL
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This is a phase I trial to determine the maximum tolerated dose (MTD) of clofarabine in a
combination with high-dose etoposide and cyclophosphamide. This is an initial step in
developing a novel myeloablative preparative regimen for autologous hematopoietic stem cell
transplantation (ASCT). While this phase I trial will initially develop the regimen in
patients with refractory disease, it is expected that it will find its best application in
patients with less advanced disease.